Algert Global LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Algert Global LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 29.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,252 shares of the biopharmaceutical company's stock after selling 42,966 shares during the quarter. Algert Global LLC owned approximately 0.07% of TG Therapeutics worth $2,438,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TGTX. NBC Securities Inc. grew its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 485 shares during the period. Quarry LP boosted its stake in TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 503 shares in the last quarter. Private Advisor Group LLC grew its holdings in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after purchasing an additional 542 shares during the period. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock valued at $109,000 after purchasing an additional 1,092 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TGTX. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price target on the stock. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded up $0.74 during midday trading on Wednesday, reaching $35.00. 1,680,767 shares of the company's stock traded hands, compared to its average volume of 3,686,240. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a one year low of $12.32 and a one year high of $36.84. The company has a market cap of $5.45 billion, a price-to-earnings ratio of -342.57 and a beta of 2.19. The stock has a 50 day moving average of $26.00 and a 200 day moving average of $21.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the prior year, the company posted $0.73 EPS. TG Therapeutics's revenue was down 49.4% on a year-over-year basis. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.